- About Us
- Our Programs
- Our Events
- uCity Square
- Support Us
Working together to identify and commercialize promising new technologies at research and academic institutions across the region
FUNDING: up to US $400,000 per project
CSL Behring is a leading global biotechnology company that develops and delivers innovative biotherapies to help people living with life threatening medical conditions live full lives. CSL has partnered with the Science Center, a nonprofit institution that is dedicated to identifying and nurturing promising technology for over half a century, to build the CSL-Science Center Research Acceleration Initiative (CSL-Sc RAI). The initiative is designed to source research and fast-track discovery through partnerships between CSL and leading life sciences research institutions. Selected projects receive funding and access to industry resources for scientists working on novel technologies in CSL’s therapeutic areas.
The Research Acceleration Initiative is a partnership, with university investigators, intended to further develop promising new technologies. The process begins with the submission of a preproposal by interested investigators. These applications should include a non-confidential description of the technology, the proposed market and a general research plan to increase the idea’s commercial readiness.
Preproposals will be reviewed within CSL, and a number of finalists will receive invitations to present in person a more detailed description of the opportunity.
Selected awardees will then be engaged by CSL with two aims. The first will be to establish a final research plan in conjunction with CSL scientists and bringing to bear CSL resources that might not be independently available to the research team. The second will be to begin negotiations with the hosting technology transfer office to formalize the relationship via a research and option agreement.
Once the research and option agreement has been executed the project will commence.
The Initiative will fund up to three proposals in 2020. Successful applicants will receive up to $200,000 per year for up to two years (maximum $400,000 funding) to accelerate translation of their research. Because the funding will be in the form of research partnerships, interested investigators must engage their institution’s technology transfer office prior to submitting an application.
Pre-proposal applications will be accepted through 5 p.m. on April 27, 2020.
The CSL – Science Center Research Acceleration Initiative seeks innovations that address CSL Therapeutic and Focus areas, and that are amenable to or include a listed Modality below:
(Emphasis on rare disease)
The CSL-Science Center Research Acceleration Initiative seeks promising new technologies relevant to CSL Behring’s mission of developing and delivering innovative biotherapies and to build new partnerships between CSL and leading research institutions.
The process has four stages:
Up to $400,000 over two years is available per technology.
Applicant technologies should have clinical application in immunology, neurology, hematology and thrombosis, transplantation, respiratory illness, or cardiovascular/metabolic diseases. CSL has interest in novel drug targets, therapeutics, and strategies for treating disease. Modalities of interest include antibodies and other protein therapeutics, and cell- and gene therapies. Small molecules are not of interest.
Applicants are reminded that the initial pre-proposal should not be regarded as confidential. Previously undisclosed or unpublished intellectual property should not be shared in this pre-proposal.
1) RESEARCH AND DEVELOPMENT PRE-PROPOSAL
The pre-proposal should be in the form of a 3-page PDF document, with single-spaced, 11-point font and 1 inch margins. Figures and illustrations are encouraged. Each application must address the following topics. Applicants should use their judgement as to how much detail is required for each element. Each section should have a written header.
Header 1: "Technology and Key Supporting Data"
Header 2: "Anticipated Market and Competing Technologies"
Header 3: "The Team"
Header 4: "Proposed Experimental Plan"
Header 5: "Use of Funds"
2) TECHNOLOGY TRANSFER OFFICE LETTER OF ENDORSEMENT
Each submission must be accompanied by a letter of support from an officer of the host institution’s Technology Transfer Office. Specifically acknowledge in the letter:
TIMELINE AND INFORMATION
March 2, 2020 Opening day for pre-proposal submissions
April 27, 2020 Deadline for receipt of pre-proposal submissions
June 25, 2020 Finalist applicants present research proposals at Science Center to CSL
July 30, 2020 Finalist applicants selected for funding
Check back soon for frequently asked questions!
Global capabilities on your doorstep
Work with one of the world's leading biotech companies
Funding for successful proposals
Access to commercial R&D, clinical, intellectual property, marketing and manufacturing expertise
Accelerate Translation of your research to deliver new therapies to patients